By


Jenrin Discovery’s IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials

See more here

By


MEBIAS Discovery LLC Presents Pre-Clinical Data on MU Opioid Receptor Pain Compounds at ADDC 

See more here

By


Intezyne Closes Oversubscribed $10M Series A Financing to Drive Rapid Oncology Portfolio Development 

See more here

By


Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes 

See more here

By


Opsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases

See more here